Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.60
- Piotroski Score 4.00
- Grade Outperform
- Symbol (KNSA)
- Company Kiniksa Pharmaceuticals, Ltd.
- Price $25.01
- Changes Percentage (4.38%)
- Change $1.05
- Day Low $23.97
- Day High $25.02
- Year High $27.92
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/28/2024
- Fiscal Year End N/A
- Average Stock Price Target $37.00
- High Stock Price Target $40.00
- Low Stock Price Target $34.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.13
- Trailing P/E Ratio 146.62
- Forward P/E Ratio 146.62
- P/E Growth 146.62
- Net Income $14.08 M
Income Statement
Quarterly
Annual
Latest News of KNSA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The 13% return this week takes Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) shareholders three-year gains to 60%
Investing in index funds provides market returns easily. However, some prefer building their own portfolios for higher returns. Kiniksa Pharmaceuticals International (NASDAQ:KNSA) grew 60% over three ...
By Yahoo! Finance | 2 months ago
